NCT00414661

Long-Term Safety Follow-Up Of Subjects Previously Enrolled In Rheumatoid Arthritis Studies Of CP-690,550

A Prospective Observational Study To Evaluate Long-Term Safety And Functional Status Of Subjects With Rheumatoid Arthritis Previously Enrolled In Studies Of CP-690,550

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 162 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to follow the health of subjects who have previously been enrolled in studies of CP-690,550 for treatment of their rheumatoid arthritis. Subjects are only eligible for this study after they have completed all participation in other studies of CP-690,550.

Detailed description

At their last visit of a qualifying study, eligible subjects will be given the opportunity to participate in this study.

Conditions

• Arthritis, Rheumatoid

Interventions

Type	Name	Description
DRUG	CP-690,550	Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.

Timeline

• Start date: 2007-04-01
• Primary completion: 2012-02-01
• Completion: 2012-02-01
• First posted: 2006-12-21
• Last updated: 2013-01-01
• Results posted: 2013-01-01

Locations

72 sites across 21 countries: United States, Argentina, Brazil, Bulgaria, Canada, Chile, Czechia, Dominican Republic, Finland, Greece, Hungary, India, Italy, Japan, Mexico, Poland, Puerto Rico, Slovakia, South Korea, Spain, Ukraine